GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (BSP:I2TC34) » Definitions » Shiller PE Ratio

Intra-Cellular Therapies (BSP:I2TC34) Shiller PE Ratio : (As of Jun. 02, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Intra-Cellular Therapies Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Intra-Cellular Therapies Shiller PE Ratio Historical Data

The historical data trend for Intra-Cellular Therapies's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Shiller PE Ratio Chart

Intra-Cellular Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Intra-Cellular Therapies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Intra-Cellular Therapies's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intra-Cellular Therapies's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Intra-Cellular Therapies's Shiller PE Ratio falls into.



Intra-Cellular Therapies Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Intra-Cellular Therapies's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Intra-Cellular Therapies's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.797/131.7762*131.7762
=-0.797

Current CPI (Mar. 2024) = 131.7762.

Intra-Cellular Therapies Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.335 100.560 -0.439
201409 -0.514 100.428 -0.674
201412 -1.374 99.070 -1.828
201503 -2.262 99.621 -2.992
201506 -1.898 100.684 -2.484
201509 -3.552 100.392 -4.662
201512 -2.600 99.792 -3.433
201603 -2.367 100.470 -3.105
201606 -2.431 101.688 -3.150
201609 -2.277 101.861 -2.946
201612 -2.147 101.863 -2.777
201703 -1.939 102.862 -2.484
201706 -1.351 103.349 -1.723
201709 -1.660 104.136 -2.101
201712 -1.845 104.011 -2.338
201803 -2.131 105.290 -2.667
201806 -2.564 106.317 -3.178
201809 -3.123 106.507 -3.864
201812 -2.913 105.998 -3.621
201903 -2.420 107.251 -2.973
201906 -2.622 108.070 -3.197
201909 -2.595 108.329 -3.157
201912 -3.037 108.420 -3.691
202003 -3.567 108.902 -4.316
202006 -4.981 108.767 -6.035
202009 -4.266 109.815 -5.119
202012 -3.910 109.897 -4.688
202103 -3.663 111.754 -4.319
202106 -4.274 114.631 -4.913
202109 -5.015 115.734 -5.710
202112 -5.938 117.630 -6.652
202203 -3.882 121.301 -4.217
202206 -4.644 125.017 -4.895
202209 -2.989 125.227 -3.145
202212 -2.360 125.222 -2.484
202303 -2.396 127.348 -2.479
202306 -2.184 128.729 -2.236
202309 -1.235 129.860 -1.253
202312 -1.470 129.419 -1.497
202403 -0.797 131.776 -0.797

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Intra-Cellular Therapies  (BSP:I2TC34) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Intra-Cellular Therapies Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Intra-Cellular Therapies (BSP:I2TC34) Business Description

Traded in Other Exchanges
Address
430 East 29th Street, New York, NY, USA, 10016
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies (BSP:I2TC34) Headlines

No Headlines